experimental conditions, the specific cognitive and sensory domains altered by perinatal tobacco exposure, thereby informing clinical investigations to better characterize nicotine dependence phenotypes in this subgroup of smokers.
The mouse model of developmental nicotine exposure could also be used to screen nicotine dependence medications. On the basis of the paucity of data on the efficacy and safety of existing pharmacotherapies for pregnant smokers, nonpharmacological (behavioral) cessation interventions are recommended as first-line treatment despite their relatively lower efficacy in the general population of smokers (Oncken and Kranzler, 2009) . Thus, by elucidating the molecular and neurobehavioral effects of perinatal exposure to cessation medications, preclinical studies can inform the clinical treatment of pregnant smokers.
Data presented by Heath et al (2010) also suggest novel molecular mechanisms important in the neurodevelopmental effects of nicotine exposure. They find that the a5 nAChR subunit expressed with a4b2 nAChRs on corticothalamic neurons has an important modulatory role in developmental cholinergic function and sensory processing. Interestingly, a common polymorphism in the a5 nAChR subunit (CHRNA5) gene has been associated with persistence of smoking during pregnancy (Freathy et al, 2009) and with the subjective effects of the initial smoking experience (Sherva et al, 2008) . The current preclinical findings (Heath et al, 2010) suggest the hypothesis that altered sensory processing is an intermediate mechanism linking CHRNA5 with nicotine dependence.
Lastly, data pointing to the corticothalamic circuit as important in nicotine's developmental effects helps to advance human neuroimaging research aimed at elucidating the functional neurocircuitry underlying nicotine dependence phenotypes. In humans, genetic variation at CHRNA5 and the severity of nicotine dependence have both been associated with reduced resting functional connectivity in a dorsal cingulate cortical circuit (Hong et al, 2010) . Thus, parallel preclinical and human studies lend support to the premise that assessment of functional cortical connectivity may be a useful translational biomarker of nicotine's effects. The preclinical data by Heath et al (2010) suggest the value of examining corticothalamic connectivity in future clinical investigations of developmental nicotine effects.
Thus, the paper by Heath et al (2010) provides an excellent example of the value of preclinical research for informing clinical research and practice. Not only does it suggest directions for human neuropsychopharmacology studies of the adverse effects of developmental nicotine, but it also highlights important translational opportunities to elucidate the functional neurobiology of nicotine addiction and develop better treatments for nicotine-addicted smokers.
